Italian Social Marketing Network Newsletter 159


Powered by

In May 2018, the National Institutes of Health
(NIH) began enrollment for a vast medical research
cohort. Named “All of Us,” it’s meant to
include 1 million U.S. volunteers, who will be studied
over 10 years at a cost of $1.45 billion.
The project promises to “lay
the scientific foundation for a new
era of personalized, highly effective
health care,” a counterpoint
to previous “‘one-size-fits-all’ medicine.”
All of Us derives from a decade’s
worth of developments in
the research world. In 2011, the
National Academies of Sciences,
Engineering, and Medicine called
for a “new taxonomy of human
disease,” stating that “opportunities
to define diseases more precisely
and to inform health-care
decisions” were “being missed.”1
Five years later, President Barack
Obama launched the Precision
Medicine Initiative. The concept
was promoted by NIH Director
Francis Collins, who defined it
as “prevention and treatment strategies
that take individual variability
into account.”2 A bandwagon
effect followed, with marked shifts
in resources and attention toward
precision medicine.
This email was sent to *|EMAIL|*

why did I get this?    unsubscribe from this list    update subscription preferences